NX-1207
Asset
Pro-apoptotic peptide (fexapotide triflutate) causing targeted prostate cell death and tissue shrinkage.
- Stage
- Phase 3
- Modality
- Peptide
- Target
- Not known
- 1
- Indication
- 1
- Trial
- 1
- Developer
Indications
1Lower urinary tract symptoms
Phase 3, Terminated, NCT02003742, clinicaltrials.gov, Oct 31, 2026
In the full profile
- Owner and partners1
- Trials1
- Aging relevance1
Every asset’s record: target, stage, trials and the evidence behind it.